The abstract is read at the publisher; the summary is JClub's.
In the National Cancer Institute–Kaiser Permanente Breast Cancer Survivors Cohort, statin therapy vs usual care showed no clear difference in 5-year CVD risk (risk ratio 1.04, 95% CI 0.86–1.25).
- Why it matters: Randomized trial evidence is limited for guiding statin use to prevent cardiovascular disease in women with breast cancer, leaving uncertainty about benefits and how to counsel patients.
- What they did: Using sequential emulation of target trials, women aged 40–84 with stages 0–III breast cancer (1993–2022), no prior CVD, no statins in 6 months, and LDL 100–160 mg/dL were compared for 5-year CVD outcomes.
- The result: Intention-to-treat estimated a 5-year risk difference of 0.3% (95% CI -0.9 to 1.5), while per-protocol gave -0.9% (95% CI -2.9 to 2.2); adherence was 48% vs 24%, implying imprecise estimates and a need to address discontinuation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.